Preview

Rational Pharmacotherapy in Cardiology

Advanced search

Search


Order results by:     
 
Issue Title
 
Vol 12, No 5 (2016) The Anticoagulation in Patients with Atrial Fibrillation: Rivaroxaban and Warfarin Abstract  similar documents
I. Yu. Koroleva, I. V. Kolesnichenko, V. P. Nosov, M. V. Zlobin, D. I. Abelevich
"... Aim. To study the effect of rivaroxaban compared with warfarin on the incidence of cardioembolic ..."
 
Vol 10, No 3 (2014) PREVENTION OF THROMBOEMBOLIC COMPLICATIONS IN ATRIAL FIBRILLATION - RAT POISON OR NEW ORAL ANTICOAGULANTS: DO WE HAVE A CHOICE, AND SHOULD WE BE AFRAID TO MAKE IT? FIRST CLINICAL EXPERIENCE WITH RIVAROXABAN IN NIZHNY NOVGOROD Abstract  similar documents
L. Y. Koroleva, I. V. Kolesnichenko, V. P. Nosov, I. I. Gritsenko, E. S. Timoschenko
"... of management of patients with atrial fibrillation. Many years of practice and experience of warfarin use ..."
 
Vol 15, No 4 (2019) Elderly Patients with Atrial Fibrillation: Focus on Comorbidity and Safety of Anticoagulant Therapy Abstract  similar documents
D. A. Napalkov, A. A. Sokolova
"... results demonstrate a favorable efficiency and safety profile of rivaroxaban in comparison with warfarin ..."
 
Vol 14, No 5 (2018) Anticoagulant Therapy in Difficult Patients with Atrial Fibrillation: When the Risks of Embolism and Bleeding Are Comparable Abstract  similar documents
D. A. Napalkov, A. A. Sokolova, M. A. Gabitova, L. N. Uddin
"... ) on rivaroxaban therapy are presented. Good efficacy and  safety  of full and  reduced doses  of rivaroxaban were ..."
 
Vol 9, No 3 (2013) ANTICOAGULANT THERAPY IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION: DRUG CHOICE AND DOSAGE ADJUSTMENT Abstract  similar documents
E. L. Dolgova, I. M. Sokolov, Yu. G. Shvarts
 
Vol 11, No 3 (2015) ANALYSIS OF THE INFLUENCE OF THROMBOEMBOLIC COMPLICATIONS PREVENTION WITH ORAL ANTICOAGULANTS ON BUDGET IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION Abstract  similar documents
A. V. Rudakova
"... and rivaroxaban). Aim. To assess the influence of apixaban use on the budget as an alternative to warfarin ..."
 
Vol 10, No 4 (2014) NEW ORAL ANTICOAGULANTS: FOCUS ON THE SAFETY Abstract  similar documents
D. A. Napalkov, A. A. Sokolova
"... dabigatran, rivaroxaban and apixaban) is presented from the standpoint of safety. The safety profile ..."
 
Vol 16, No 1 (2020) Control Of Anticoagulation Therapy in Atrial Fibrillation (COAT-AF Study) in Real Clinical Practice Abstract  similar documents
A. A. Zarudsky, A. A. Gavrilova, Т. S. Filinichenko
"... and systemic thromboembolism. For patients that were treated by warfarin international normalization ratio (INR ..."
 
Vol 8, No 4 (2012) THE RISK OF BLEEDINGS IN PATIENTS WITH ATRIAL FIBRILLATION DURING ANTICOAGULANT THERAPY Abstract  similar documents
M. Yu. Gilyarov
"... . Along with traditional drugs (acetylsalicylic acid, warfarin) rivaroxaban is specially considered ..."
 
Vol 8, No 3 (2012) RIVAROXABAN IN THE PREVENTION OF THROMBOEMBOLIC COMPLICATIONS IN PATIENTS WITH ATRIAL FIBRILLATION Abstract  similar documents
M. Yu. Gilyarov
"... -salicylic acid, warfarin). Efficacy and safety of rivaroxaban is considered on the basis of the results ..."
 
Vol 14, No 5 (2018) Bayer registered a new indication for rivaroxaban for use in patients with coronary heart disease or peripheral artery disease in the European Union and USA Abstract  similar documents
Bayer Company Press Release
"... антикоагулянта ривароксабана в дозе 2,5 мг 2 р/д в сочетании с 75-100 мг ацетилсалициловой кислоты один раз в ..."
 
Vol 15, No 5 (2019) Rivaroxaban-Associated Hepatotoxicity: a Clinical Case and Literature Review Abstract  similar documents
B. A. Tatarsky, N. V. Kazennova, D. A. Napalkov
"... .g. warfarin), have a predictable manifestation of the anticoagulant effect and the possibility of using ..."
 
Vol 11, No 1 (2015) PHARMACOECONOMIC ASPECTS OF APIXABAN FOR PREVENTION OF THROMBOEMBOLIC EVENTS IN PATIENTS WITH ATRIAL FIBRILLATION Abstract  similar documents
A. V. Rudakova
"... of care warfarin and aspirin, novel oral anticoagulants rivaroxaban and dabigatran. At the same time ..."
 
Vol 15, No 2 (2019) Studies of Anticoagulant Therapy in Frail Elderly Patients: Problems of Terminology and Methodology Abstract  similar documents
S. N. Bel'diev, I. V. Medvedeva, D. Yu. Platonov, G. Yu. Trufanova
"... for two RCTs with rivaroxaban - EINSTEIN-DVT and EINSTEIN-PE) contained data on the participation of frail ..."
 
Vol 12, No 5 (2016) Features of Modern Anticoagulant Therapy in Patients with Nonvalvular Atrial Fibrillation and Chronic Kidney Disease Abstract  similar documents
I. S. Daabul, A. A. Sokolova, D. A. Napalkov
"... of the main studies didn't yield or exceeded warfarin concerning balance of efficiency and safety. However ..."
 
Vol 12, No 5 (2016) Dabigatran Etexilate in the course of Electrical Cardioversion in Patients with Non-Valvular Atrial Fibrillation Abstract  similar documents
N. A. Novikova, A. N. Volovchenko
"... cardioversion. Vitamin K antagonists (warfarin) more often used to prepare for electrical cardioversion. However ..."
 
Vol 12, No 2 (2016) THE EFFICACY AND SAFETY OF NEW ORAL ANTICOAGULANTS IN PATIENTS WITH ATRIAL FIBRILLATION IN CLINICAL PRACTICE Abstract  similar documents
S. V. Moiseev
"... New oral anticoagulants that inhibit factor Xa (rivaroxaban, apixaban, edoksaban) or thrombin ..."
 
Vol 12, No 4 (2016) Clinical significance of new oral anticoagulants in the prevention of thromboembolic complications in patients with atrial fibrillation: not all dreams come true Abstract  similar documents
Yu. A. Bunin, S. V. Miklishanskaya
"... of them oral anticoagulants were used mainly from the group of vitamin K antagonists, most often warfarin ..."
 
Vol 13, No 5 (2017) WARFARIN AND ITS IMPORTANCE IN THE ERA OF NEW ORAL ANTICOAGULANTS. ISSUES OF MONITORING THE EFFECTIVENESS AND SAFETY OF TREATMENT Abstract  similar documents
S. Yu. Martsevich, Y. V. Lukina
"... " of the OAC is warfarin, which has proved effectiveness in all categories of patients with AF. A whole group ..."
 
Vol 10, No 3 (2014) COST-EFFECTIVENESS OF APIXABAN AS COMPARED WITH WARFARIN AND ACETYLSALICYLIC ACID IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION IN THE RUSSIAN FEDERATION Abstract  similar documents
A. V. Rudakova, V. A. Parfenov
"... K antagonists (such as warfarin), antiplatelet therapy (such as acetylsalicylic acid) and novel oral ..."
 
Vol 13, No 5 (2017) ADHERENCE TO THE USE OF NEW ORAL ANTICOAGULANTS IN PATIENTS WITH ATRIAL FIBRILLATION – THE WAY TO SOLVE THE PROBLEM OF EFFICACY AND SAFETY OF TREATMENT Abstract  similar documents
S. G. Kanorskii
"... of anticoagulant therapy include vitamin K antagonists, such as warfarin, whose  benefits are long established ..."
 
Vol 14, No 4 (2018) Possibilities of Using Rivaroxaban in Elderly Patients with Atrial Fibrillation: Data from Randomized Studies and Real Clinical Practice Abstract  similar documents
N. M. Vorobyeva, O. N. kacheva
"... The possibility of rivaroxaban using in elderly patients with non-valvular atrial fibrillation ..."
 
Vol 8, No 4 (2012) WARFARIN IN PATIENTS WITH CARDIOEMBOLIC STROKE Abstract  similar documents
E. N. Dankovtseva, S. L. Arkhipov, D. A. Zateyshchikov
"... Analysis of the current literature data on the use of warfarin in patients with cardioembolic ..."
 
Vol 7, No 5 (2011) ANALYSIS OF DIRECT COSTS ASSOCIATED WITH THE USE OF WARFARIN IN PATIENTS WITH ATRIAL FIBRILLATION Abstract  similar documents
Yu. B. Belousov, I. S. Yavelov, D. Yu. Belousov, E. V. Afanasieva
"... Aim. To analyze the structure of expenses associated with warfarin dose adjustment ..."
 
Vol 7, No 1 (2011) ANTITHROMBOTIC THERAPY IN ATRIAL FIBRILLATION: NEW DATA AND NEW HORIZONS Abstract  similar documents
M. Yu. Gilyarov, V. A. Sulimov
"... fibrillation. Factors of warfarin therapy efficacy, as well as the possibility of new antithrombotic drugs ..."
 
Vol 15, No 5 (2019) Clinical Case: Atypical Warfarin-induced Skin Necrosis Abstract  similar documents
T. V. Kondratieva, L. V. Popova, S. S. Karachev, A. S. Lishuta, M. Z. Kanevskaya
"... Warfarin-induced skin necrosis (WISN) is a rare complication of antivitamin K therapy, which occurs ..."
 
Vol 16, No 1 (2020) Decrease in Efficacy of Warfarin as a Result of Drug-Drug Interaction (Case Report) Abstract  similar documents
N. T. Vatutin, G. G. Taradin, G. A. Ignatenko, E. S. Gasendich, A. V. Harchenko, I. B. Povaljaeva
"... considering a frequent administration of several drugs having different drug-drug interactions. Warfarin ..."
 
Vol 13, No 5 (2017) DRUG INTERACTIONS OF NEW ORAL ANTICOAGULANTS: INSIDE AND OUTSIDE TABLE CELLS Abstract  similar documents
S. N. Bel'diev, I. V. Medvedeva, D. Yu. Platonov
"... The opinion is expressed in some  domestic publications that  rivaroxaban has  the  most ..."
 
Vol 12, No 4 (2016) Application of rivaroxaban in clinical practice: results of a prospective observational study XANTUS in patients with atrial fibrillation Abstract  similar documents
S. G. Kanorskii
"... In XANTUS study the safety and efficacy of factor Xa inhibitor rivaroxaban were evaluated ..."
 
Vol 13, No 1 (2017) CLINICAL AND ECONOMICAL COMPARISON OF RIVAROXABAN AND APIXABAN USE IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION Abstract  similar documents
S. V. Nedogoda, I. N. Barykina, A. S. Salasiuk, V. O. Smirnova
"... Aim. To compare cost-effectiveness of the use of direct factor Xa inhibitors rivaroxaban ..."
 
Vol 6, No 5 (2010) THE INVASIVE DENTAL PROCEDURES IN PATIENTS TREATING WITH WARFARIN: POSSIBILITIES AND PROSPECTS FOR SAFETY Abstract  similar documents
T. V. Kozlova, I. M. Makeyeva, V. Y. Doroshina, S. I. Bokareva
"... in the perioperative continuation or termination of warfarin therapy is shown. Potential of the local hemostatic agents ..."
 
Vol 5, No 3 (2009) SAFETY OF LONGTERM THERAPY WITH WARFARIN: POSSIBILITY OF TREATMENT RENEWING AFTER HEMORRHAGIC COMPLICATIONS Abstract  similar documents
E. S. Kropacheva
"... The safety of anticoagulant therapy is discussed. Warfarin position in prevention of thrombotic ..."
 
Vol 6, No 4 (2010) ANTITHROMBOTIC THERAPY IN NONVALVULAR ATRIAL FIBRILLATION: PROBLEMS AND PROSPECTS Abstract  similar documents
A. Y. Rychkov, N. Y. Khor'kova, A. A. Bliznyakov
"... Appropriate use of warfarin is not in routine clinical practice despite convincing data ..."
 
Vol 8, No 2 (2012) QUALITY OF LIFE AND ITS DYNAMICS IN PATIENTS WITH ATRIAL FIBRILLATION AFTER LEAVING THE INTERNATIONAL CLINICAL TRIAL Abstract  similar documents
E. L. Artanova, L. E. Kon'shina, I. M. Sokolov, Y. G. Shvarts
"... with warfarin after leaving the international clinical trial. Material and Methods. Patients with AF who were ..."
 
Vol 14, No 6 (2018) Anticoagulant Therapy in “Fragile” Elderly Patients: Current State of the Problem Abstract  PDF (Eng)  similar documents
N. M. Vorobyeva, O. N. Tkacheva
"... showed that only therapy with rivaroxaban (out of three direct oral anticoagulants) compared ..."
 
Vol 14, No 5 (2018) Excessive Hypocoagulation in Therapy with Warfarin within Polypharmacy: Using online database Multi-Drug Interaction Checker and Graphic “Time-Effect-Drug Administration” to Eliminate Adverse Drug Event (Case Report) Abstract  similar documents
G. S. Krasnov, I. V. Kazancev
"... . As a result of analysis, it was  described two  drug  interactions led to minor bleeding: warfarin ..."
 
Vol 12, No 1 (2016) Interaction of rivaroxaban with amiodarone, verapamil and diltiazem in patients with atrial fibrillation: terra incognita Abstract  similar documents
S. N. Bel'diev
"... Currently there are no generally accepted guidelines for the use of rivaroxaban together ..."
 
Vol 11, No 2 (2015) ANTICOAGULANT THERAPY IN EVERYDAY CLINICAL PRACTICE: DATA OF THE RETROSPECTIVE CROSS-SECTIONAL STUDY Abstract  PDF (Eng)  similar documents
V. A. Sulimov, D. A. Napalkov, A. A. Sokolova, A. V. Jilenko, O. S. Anikina
"... % of the patients received appropriate anticoagulant therapy. Warfarin was prescribed in 73% of the cases, of them ..."
 
Vol 13, No 1 (2017) DATA OF CLINICAL PRACTICE AS A TOOL FOR CHOICE OF DIRECT ORAL ANTICOAGULANT Abstract  similar documents
D. А. Napalkov, A. A. Sokolova, V. V. Fomin
"... was previously demonstrated in ARISTOTLE trial. On the contrary, rivaroxaban was associated with the most ..."
 
Vol 13, No 3 (2017) PHARMACOGENETIC ASPECTS OF NEW ORAL ANTICOAGULANTS APPLICATION Abstract  similar documents
A. V. Kryukov, D. A. Sychev, O. V. Tereshchenko
"... of genotype on rivaroxaban pharmacokinetics in the study involving the carriers of ABCB1 gene rs2032582 and rs ..."
 
Vol 7, No 5 (2011) ANTITHROMBOTIC THERAPY IN ATRIAL FIBRILLATION: RECENT APPROACHES AND NEAR PERSPECTIVES Abstract  similar documents
Ya. P. Dovgalevskiy, L. E. Kuvshinova, I. V. Graifer, N. V. Furman, P. Ya. Dovgalevskiy
 
Vol 9, No 4 (2013) COMPARATIVE EFFICACY AND SAFETY OF NEW ORAL ANTICOAGULANTS Abstract  similar documents
V. A. Sulimov, D. A. Napalkov, A. A. Sokolova
 
Vol 12, No 3 (2016) THE ADVANCED TACTICS OF THE MANAGEMENT OF PATIENTS WITH VENOUS THROMBOEMBOLISM: THE ROLE OF RIVAROXABAN AT VARIOUS STAGES OF TREATMENT Abstract  PDF (Eng)  similar documents
S. R. Gilyarevskiy
"... the validity of monotherapy tactics with rivaroxaban in patients with VTE. The results of this study ..."
 
Vol 14, No 2 (2018) NEW DIRECT ORAL ANTICOAGULANTS FOR TREATMENT OF PATIENTS WITH ATRIAL FIBRILLATION IN REAL-WORLD SETTING Abstract  similar documents
Zh. D. Kobalava, S. V. Villevalde, A. A. Shavarov
"... and systemic thromboembolic (STE) complications as warfarin, although DOACs were associated with less risk ..."
 
Vol 7, No 4 (2011) SPECIAL CONSIDERATIONS REGARDING WARFARIN DOSE TITRATION IN PATIENTS WITH ATRIAL FIBRILLATION DEPENDING ON CLINICAL FACTORS Abstract  similar documents
E. L. Artanova, E. V. Saleeva, I. M. Sokolov, Y. G. Shvarts
"... Aim. To study the relations of clinical characteristics and individual warfarin dose titration ..."
 
Vol 9, No 4 (2013) COMPARISON OF DIRECT COSTS OF DABIGATRAN AND WARFARIN THERAPY IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION DURING PREPARATION FOR ELECTIVE CARDIOVERSION IN THE REAL CLINICAL PRACTICE Abstract  similar documents
L. E. Kuvshinova, N. V. Furman, P. V. Dolotovskaya, Ya. P. Dovgalevsky
"... Aim. To compare direct medical costs of dabigatran and warfarin therapy in patients with non ..."
 
Vol 7, No 2 (2011) PECULIAR PROPERTIES OF ANTITHROMBOTIC THERAPY IN PATIENTS WITH ARTERIAL HYPERTENSION. IS IT POSSIBLE TO DO THE TREATMENT SAFE? Abstract  similar documents
I. V. Zotova, D. A. Zateyshchikov
 
Vol 15, No 4 (2019) Safety of Using Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Chronic Kidney Disease Abstract  similar documents
V. I. Petrov, O. V. Shatalova, A. S. Gerasimenko, V. S. Gorbatenko
"... complications in atrial fibrillation, including those with concomitant renal pathology, was considered warfarin ..."
 
Vol 14, No 6 (2018) The Results of Rivaroxaban Studies COMMANDER HF and MARINER Were Published. Bayer Company Press Release . Abstract  PDF (Eng)  similar documents
artilce Editorial
 
Vol 13, No 2 (2017) RIVAROXABAN HAS DEMONSTRATED AN ADVANTAGE OVER ACETYLSALICYLIC ACID IN PREVENTING THE RECURRENCE OF VENOUS THROMBOEMBOLIC EVENTS IN THE EINSTEIN CHOICE STUDY Abstract  similar documents
. Editorial
"... эффективность и безопасность ривароксабана в дозах 20 мг 1 р/д*, 10 мг 1 р/д и ацетилсалициловой кислоты в дозе ..."
 
Vol 16, No 1 (2020) Clinical Significance of Thrombin Blockade with Low Doses (2.5 mg) of Rivaroxaban in Ischemic Heart Disease Patients Abstract  similar documents
A. B. Sumarokov, L. I. Buryachkovskaya, Y. V. Docenko, M. S. Kurochkin, N. V. Lomakin
"... of antiplatelet therapy. The combination of rivaroxaban in a dose of 2.5 mg and standard double antiplatelet ..."
 
Vol 8, No 1 (2012) PHARMACOECONOMIC EVALUATION OF DABIGATRAN VS WARFARIN IN CARDIOVASCULAR EVENTS PREVENTION IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION Abstract  similar documents
Yu. B. Belousov, V. Yu. Mareev, I. S. Yavelov, D. Yu. Belousov
"... the cost-effectiveness of dabigatran etexilate versus warfarin prescribed in “real-world” settings from ..."
 
Vol 14, No 1 (2018) THE CONTROL OF INTERNATIONAL NORMALISED RATIO IN PATIENTS WITH ATRIAL FIBRILLATION TREATED WITH WARFARIN IN OUTPATIENT AND HOSPITAL SETTINGS: DATA FROM RECVASA REGISTRIES Abstract  similar documents
M. M. Loukianov, S. Yu. Martsevich, S. S. Yakushin, A. N. Vorobyev, K. G. Pereverzeva, A. V. Zagrebelnyy, V. Val. Yakusevich, V. Vl. Yakusevich, T. A. Gomova, M. N. Valiakhmetov, V. P. Mikhin, Yu. V. Maslennikova, M. A. Bichurina, L. A. Matskevich, E. N. Belova, V. G. Klyashtorny, E. V. Kudryashov, A. D. Deev, O. M. Drapkina, s. A. Boytsov
"... in patients with atrial fibrillation (AF) receiving anticoagulant therapy with warfarin. Material and methods ..."
 
Vol 10, No 2 (2014) RIVAROXABAN IN PATIENTS STABILIZED AFTER A ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION. RESULTS FROM THE ATLAS ACS-2–TIMI-51 TRIAL Abstract  similar documents
J. L. Mega, E. Braunwald, S. A. Murphy, A. N. Plotnikov, P. Burton, R. G. Kiss, A. Parkhomenko, M. Tendera, P. Widimsky, C. M. Gibson
"... Цель. Представлен анализ лечения ривароксабаном в заранее определенной подгруппе больных инфарктом ..."
 
Vol 11, No 5 (2015) New data of the real clinical practice confirms low incidence of major bleeding when using rivaroxaban in patients with non-valvular atrial fibrillation Abstract  similar documents
article Editorial
"... rivaroxaban in patients with non-valvular atrial fibrillation  ..."
 
Vol 13, No 6 (2017) PREDICTORS OF THE RISK OF HEMORRHAGIC EVENTS IN PATIENTS WITH ATRIAL FIBRILLATION RECEIVING LONGTERM THERAPY WITH DIRECT ORAL ANTICOAGULANTS Abstract  similar documents
A. А. Sokolova, A. V. Zhilenko, I. L. Tsarev,, D. A. Napalkov, V. V. Fomin
"... – rivaroxaban and apixaban) were included into the cohort study in parallel groups. In addition to evaluate ..."
 
Vol 14, No 4 (2018) Hepatotoxicity of New Oral Anticoagulants Abstract  similar documents
A. R. Kasimova, A. V. Philippova (Guryanova), A. S. Kolbin
 
Vol 15, No 3 (2019) Treatment of Patients with Stable Manifestations of Atherosclerosis: New Opportunities Abstract  similar documents
article Editorial
"... of both coagulation and platelet). Experts noted that combination of rivaroxaban 2.5 mg BID ..."
 
Vol 15, No 6 (2019) Safety of Non-Vitamin K Oral Anticoagulants in Elderly Patients with Atrial Fibrillation Abstract  similar documents
M. A. Gabitova, P. M. Krupenin, A. A. Sokolova, D. A. Napalkov, V. V. Fomin
"... of age with confirmed AF, receiving dabigatran in a reduced dosage, apixaban or rivaroxaban in full ..."
 
Vol 15, No 6 (2019) New Opportunities for Improving the Prognosis of Patients with Chronic Ischemic Heart Disease Abstract  similar documents
N. B. Perepech
"... , which obtained confirmation of the positive effect of combined therapy with rivaroxaban ..."
 
Vol 16, No 1 (2020) The Efficacy, Safety and Adherence to Treatment when New Anticoagulants Taking in Over 75 Years Old Patients with Atrial Fibrillation Abstract  similar documents
A. N. Turov, S. V. Panfilov, О. V. Tschiglinzeva
"... , rivaroxaban – in 41.3% (n=178), apixaban – in 20.2% (n=87) of patients. Results. The incidence of new cases ..."
 
Vol 14, No 1 (2018) NEW APPROACHES TO INDIVIDUALIZED CHOICE OF ORAL ANTICOAGULANTS IN PATIENTS WITH ATRIAL FIBRILLATION Abstract  similar documents
Ju. P. Skirdenko, N. A. Nikolayev
"... of food products that can affect anticoagulant therapy with warfarin does not have special regional ..."
 
Vol 2, No 3 (2006) ANTITHROMBOTIC THERAPY OF ISCHEMIC HEART DISEASE: FROM FAST ACTING ANTIAGGREGANTS TO STATINES AND NITRATE OXIDE. IS IT REAL? Abstract  similar documents
I. A. Latfullin, A. A. Podolskaya
"... , warfarin, ticlopidine and clopidogrel are discussed. Study data on new antiplatelet drugs are given ..."
 
Vol 15, No 1 (2019) Assessment of Antithrombotic Therapy in Patients with Atrial Fibrillation for 2015-2017 According to the Registry of the Clinic of the Scientific Research Institute of Medical Problems of the North of Krasnoyarsk City Abstract  similar documents
A. A. Tuchkov, N. G. Gogolashvili, R. A. Yaskevich
"... % at the prehospital stage, of which 19.8% of patients took warfarin and 12.2% – direct OAC. The target level ..."
 
Vol 12, No 2 (2016) ATRIAL FIBRILLATION AND ISCHEMIC HEART DISEASE: HOW TO COMBINE ANTIPLATELET AND ANTICOAGULANT THERAPY, DEPENDING ON THE CLINICAL SITUATION? Abstract  similar documents
D. A. Napalkov, A. A. Sokolova, A. V. Rodionov
"... and safety of apixaban with these of warfarin in patients with atrial fibrillation and a history of ischemic ..."
 
Vol 12, No 5 (2016) Treatment Adherence as a New Choice Factor for Optimization of Oral Anticoagulation Therapy in Patients with Atrial Fibrillation and Hemostatic Gene Polymorphisms Abstract  PDF (Eng)  similar documents
Yu. P. Skirdenko, A. V. Shustov, V. V. Zherebilov, N. A. Nikolayev
"... compared with patients of warfarin group. Mutations in CYP2C9 gene were detected in 32.9%, VKORC1 – in 68 ..."
 
Vol 9, No 5 (2013) APPLICATIONS OF PHARMACOGENETIC TESTING FOR PERSONALIZATION OF THERAPY WITH ORAL ANTICOAGULANTS IN RUSSIA Abstract  similar documents
D. A. Sychev, R. E. Kazakov, V. A. Otdelenov, A. B. Prokofiev
"... response to oral anticoagulants is considered. Possible tactics of warfarin dosing and new oral ..."
 
Vol 7, No 4 (2011) LEFT VENTRICULAR CLOT LYSIS DUE TO COMBINED ANTICOAGULANT THERAPY WITH WARFARIN AND FRAXIPARINE IN PATIENT WITH DILATED CARDIOMYOPATHY AND CHRONIC HEART FAILURE. THE CLINICAL CASE Abstract  similar documents
O. V. Uskova, K. O. Sobolev, G. E. Gendlin, A. V. Melekhov
"... anticoagulant therapy with warfarin and fraxiparine in patient with dilated cardiomyopathy, congestive heart ..."
 
Vol 13, No 5 (2017) RIVAROXABAN OF THE BAYER COMPANY SIGNIFICANTLY (BY 24%) REDUCES THE RISK OF STROKE, CARDIOVASCULAR DEATH AND MYOCARDIAL INFARCTION IN PATIENTS WITH CHRONIC ISCHEMIC HEART DISEASE OR PERIPHERAL ARTERIAL DISEASE Abstract  similar documents
статья Редакционная
 
Vol 8, No 5 (2012) RISK OF THROMBOEMBOLIC COMPLICATIONS AND ANTITHROMBOTIC THERAPY IN IN-PATIENTS WITH PERMANENT AND RECURRENT ATRIAL FIBRILLATION IN REAL CLINICAL PRACTICE Abstract  similar documents
I. V. Grajfer, L. E. Kuvshinova, P. V. Dolotovskaya, O. V. Reshet'ko, N. V. Furman
"... fibrillation (AF) with the risk level of thromboembolic complications (TEC), calculated with the СHADS2 and CHA ..."
 
Vol 15, No 5 (2019) Anticoagulant Therapy as a Tool for the Prevention of Cognitive Impairment Associated with Atrial Fibrillation Abstract  similar documents
O. D. Ostroumova, A. I. Kochetkov, S. P. Korchagina, T. M. Ostroumova, M. S. Chernyaeva, A. A. Kirichenko
"... strategy for preventing stroke associated with AF. Among the DOAC class, rivaroxaban is worth noticing ..."
 
Vol 15, No 4 (2019) The Therapy with Oral Anticoagulants in Patients with Atrial Fibrillation in Outpatient and Hospital Settings (Data from RECVASA Registries) Abstract  similar documents
M. M. Loukianov, S. Yu. Martsevich, O. M. Drapkina, S. S. Yakushin, A. N. Vorobyev, K. G. Pereverzeva, A. V. Zagrebelnyy, V. Val. Yakusevich, V. Vl. Yakusevich, E. M. Pozdnyakova, T. A. Gomova, E. E. Fedotova, M. N Valiakhmetov, V. P. Mikhin, Yu. V. Maslennikova, E. Y. Andreenko, V. G. Klyashtorny, E. V. Kudryashov, E. Yu. Okshina, M. A. Panagopulu, S. A. Boytsov
"... (1335 from 3169 patients; age 69.1±10.4 years, 43% men), including warfarin (817 patients; 26%) and non ..."
 
Vol 14, No 6 (2018) Antithrombotic Therapy in Patients with Atrial Fibrillation after Myocardial Infarction: Clinical Guidelines and Actual Practice Abstract  PDF (Eng)  similar documents
K. G. Pereverzeva, S. S. Yakushin, A. E. Pripadcheva, N. P. Agaltsova
"... + antiplatelet agent) and 1 (1.0%) case – a monotherapy. Among all cases of OAC prescription warfarin ..."
 
Vol 12, No 6 (2016) NEW DATA OF EXTENSIVE RESEARCH PROGRAM AND THE RESULTS OF STUDIES IN REAL CLINICAL PRACTICE FROM DIFFERENT COUNTRIES REAFFIRMED THE HIGH EFFICACY AND A FAVORABLE SAFETY PROFILE OF RIVAROXABAN (XARELTO®) FROM THE BAYER COMPANY PRESS RELEASE OF THE BAYER COMPANY Abstract  similar documents
article editorial
 
Vol 9, No 2 (2013) ERA OF NEW ANTICOAGULANTS IN THE TREATMENT OF NON-VALVULAR ATRIAL FIBRILLATION: PROSPECTS AND CHALLENGES Abstract  similar documents
Z. M. Safiullina, S. V. Shalaev
"... inhibitors of coagulation factor Xa (rivaroxaban, apixaban), in the treatment of nonvalvular atrial ..."
 
Vol 8, No 6 (2012) HOW TO USE DABIGATRAN IN PATIENTS WITH ATRIAL FIBRILLATION Abstract  similar documents
S. V. Moiseev
"... clinical trial dabigatran 150 mg b.i.d was more effective than warfarin in prevention of ischemic stroke ..."
 
Vol 9, No 6 (2013) THE ROLE OF P-GLYCOPROTEIN IN RATIONAL PHARMACOTHERAPY IN CARDIOLOGY Abstract  similar documents
A. V. Shulkin, E. N. Yakusheva, N. M. Popova
"... , prasugrel) and anticoagulants (dabigatran etexilate, rivaroxaban, edoxaban) is not feasible in routine ..."
 
Vol 10, No 2 (2014) ANALYSIS OF ANTITHROMBOTIC THERAPY IN IN-PATIENTS WITH PERMANENT ATRIAL FIBRILLATION (PHARMACOEPIDEMIOLOGY STUDY) Abstract  similar documents
V. I. Petrov, O. V. Shatalova, A. S. Maslakov
"... . Acetylsalicylic acid was prescribed to 0.7% of cases (n=2), warfarin – to 5% (n=12). High risk of thromboembolic ..."
 
Vol 10, No 2 (2014) SECONDARY PREVENTION OF STROKE IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION: THE CLINICIANS’ VIEWPOINT Abstract  similar documents
E. A. Drozdova
"... assessment of warfarin and dabigatran therapies is given. ..."
 
Vol 14, No 3 (2018) APPROACHES TO THE CHOICE OF ANTICOAGULANT THERAPY IN THE TREATMENT OF PATIENTS WITH COMBINATION OF ATRIAL FIBRILLATION WITH CORONARY HEART DISEASE OR PERIPHERAL ATHEROSCLEROSIS: POTENTIAL OF APIXABAN Abstract  similar documents
O. D. Ostroumova, A. I. Kochetkov, I. Yu. Orlova, E. A. Smolyarchuk, J. S. Pavlova
"... oral anticoagulants (NOAC) instead of vitamin K antagonists (eg, warfarin), low doses of NOAC, studied ..."
 
Vol 9, No 5 (2013) PRACTICAL APPLICATION OF DABIGATRAN ETEXILATE FOR STROKE PREVENTION IN PATIENTS WITH ATRIAL FIBRILLATION Abstract  similar documents
E. D. Kosmacheva, S. G. Kanorskiy, A. A. Kastanayan, N. V. Haylo, D. B. Goltyapin, E. A. Lipnitskaya, M. E. Statsenko
"... Disadvantages of vitamin K antagonist warfarin and the benefits of new anticoagulants, including ..."
 
Vol 11, No 5 (2015) Cost-effectiveness of new oral anticoagulants in the treatment and secondary prevention of venous thromboembolism Abstract  similar documents
A. V. Rudakova
"... of venous thromboembolism (VTE) compared with low molecular weight heparin (LMWH)/warfarin and other new ..."
 
Vol 7, No 6 (2011) CORONARY EMBOLISM WITH FRAGMENTED THROMBUS FROM THE LEFT VENTRICLE IN PATIENT WITH POSTINFARCTION ANEURYSM Abstract  similar documents
Yu. F. Salakhova, S. V. Gar'kina, T. V. Kislukhin, D. V. Duplyakov, V. S. Ivanov, E. R. Perunova, E. I. Bazhenova, S. E. Burnazyan, S. M. Khokhlunov
"... therapy (acetylsalicylic acid, clopidogrel, warfarin) was made on the 4th day of disease onset taking ..."
 
Vol 10, No 6 (2014) THE ASSESSMENT OF COMPLIANCE TO THE USE OF NEW ORAL ANTICOAGULANTS IN PATIENTS WITH ATRIAL FIBRILLATION ACCORDING TO THE PROFILE REGISTER Abstract  similar documents
S. Y. Martsevich, A. R. Navasardyan, N. P. Kutishenko, A. V. Zakharova, V. P. Voronina, N. A. Dmitrieva, L. Yu. Lrozdova, A. V. Zagrebelnyy, O. V. Lerman, Yu. V. Lukina, G. V. Martynova, A. A. Nikulina, G. S. Ryazanova, A. Yu. Suvorov, S. N. Tolpygina
"... refusal were satisfactory with warfarin (32.6%), the high price of these drugs (23.9%), the description ..."
 
Vol 12, No 4 (2016) New data from clinical practice again confirmed the high efficacy and a favorable safety profile of the drug Xarelto® in patients with atrial fibrillation (Press release of the company Bayer) Abstract  similar documents
Article Editorial
"... внутричерепных кровотечений на фоне терапии препаратом Ксарелто® (ривароксабан) по сравнению с варфарином у ..."
 
Vol 13, No 1 (2017) ANTIPLATELET THERAPY OF ATRIAL FIBRILLATION: FOCUS ON THE ELDERLY Abstract  similar documents
E. А. Ushkalova, S. K. Zyryanov, E. V. Dumchenko
"... anticoagulants. Combined therapy of antiplatelet drugs with warfarin or new oral anticoagulants results ..."
 
Vol 9, No 2 (2013) ANTITHROMBOTIC THERAPY SAFETY MONITORING BASED ON SPONTANEOUS REPORTS Abstract  similar documents
O. V. Shatalova, O. N. Smuseva, A. S. Maslakov
"... .2% (4/18), and antiplatelet drugs 11.1% (2/18). Conclusion. Warfarin was more often cause of ADR during ..."
 
Vol 10, No 6 (2014) THE PROBLEM OF THE USE OF NEW ORAL ANTICOAGULANTS IN CANCER PATIENTS RECEIVING CHEMOTHERAPY Abstract  similar documents
A. A. Rumyantsev, I. A. Pokataev, T. V. Kozlov, N. A. Rumyantsev
"... for anticoagulant prevention. Besides, heparin and warfarin use for VTE prevention in cancer is accompanied by some ..."
 
Vol 3, No 2 (2007) VARFARIN DOSE REGIME APPROACHS BASED ON PHARMACOGENETICS TEST RESULTS: REAL POSSIBILITY TO OPTIMIZE THE PHARMACOTHERAPY Abstract  similar documents
D. A. Sychev, I. M. Antonov, S. V. Zagrebin, N. A. Gasanov, V. G. Kukes
 
Vol 14, No 4 (2018) Physician’s Adherence to Clinical Guidelines for in-Hospital Anticoagulant Prescribing Abstract  similar documents
A. A. Chernov, E. V. Kleymenova, D. A. Sychev, L. P. Yashina, M. D. Nigmatkulova, V. A. Otdelenov, S. A. Payushchik
"... patients, including warfarin (39.5%), direct oral anticoagulants (DOAC) (46.5%) and low-molecular weight ..."
 
Vol 14, No 3 (2018) THROMBOSIS OF LEFT ATRIAL APPENDAGE DURING THERAPY WITH DIRECT ORAL ANTICOAGULANT. CLINICAL CASE Abstract  similar documents
I. S. Daaboul, S. Yu. Koroleva, A. A. Kudrjavtseva, A. A. Sokolova, D. A. Napalkov, V. V. Fomin
"... of thromboembolic complications. In connection with the categorical refusal of the patient from warfarin ..."
 
Vol 12, No 4 (2016) The use of oral anticoagulants in patients with atrial fibrillation: cohort study data Abstract  similar documents
O. V. Gaisenok, A. S. Leonov
"... . Results. The rate of OAC use was 46.5% (warfarin – 22.4%, NOAC – 20.7%), antiplatelet agents use – 60 ..."
 
Vol 10, No 6 (2014) PHARMACOEPIDEMIOLOGIC ANALYSIS OF HOSPITAL TREATMENT OF PATIENTS WITH CEREBRAL INFARCTION AND ATRIAL FIBRILLATION Abstract  similar documents
N. V. Mikheeva, O. V. Reshetko, N. V. Furman
"... .12.2011. Results. Acetylsalicylic acid was prescribed to 66.7% of patients, warfarin – 3.9%. At that target level ..."
 
Vol 9, No 2 (2013) LYUBERTSY STUDY ON MORTALITY RATE IN PATIENTS AFTER CEREBRAL STROKE OR TRANSIENT ISCHEMIC ATTACK (LIS-2). DESIGN AND MEDICAL TREATMENT ESTIMATION Abstract  PDF (Eng)  similar documents
S. A. Boytsov, S. Yu. Martsevich, M. L. Ginzburg, N. P. Kutishenko, L. Yu. Drozdova, A. V. Akimova, A. Yu. Suvorov, M. M. Loukianov, N. A. Dmitrieva, O. V. Lerman, N. Yu. Zhuravskaya, E. V. Daniels, A. V. Fokina, V. N. Yudaev, V. P. Smirnov, A. M. Kalinina, S. V. Kotov, L. V. Stahovskaya
"... , 4 (1%) – warfarin. Statins intake was recommended to 3 (1%) patients. Conclusion. We revealed low ..."
 
Vol 14, No 2 (2018) New Possibilities of Antithrombotic Therapy of Patients with Peripheral and Widespread Atherosclerotic Lesion Abstract  similar documents
A. L. Komarov, Е. S. Novikova, E. V. Guskova, Е. B. Yarovaya, A. N. Samko, E. Р. Panchenko
"... , that was demonstrated in a recently published study COMPASS. Treatment with rivaroxaban small doses in addition ..."
 
Vol 14, No 2 (2018) WHAT DO PATIENTS WITH ATRIAL FIBRILLATION KNOW ABOUT STROKE AND SYSTEMIC EMBOLISM PREVENTION? DATA OF THE PRIMA-TERRA REGISTRY Abstract  similar documents
R. М. Linchak, O. G. Kompaniyets, A. M. Nedbaykin
"... warfarin, 15% new oral anticoagulants (NOAC). The majority of patients received antiplatelet agents ..."
 
Vol 15, No 1 (2019) Comparative Analysis of Antithrombotic Therapy in In-Patients with Atrial Fibrillation Abstract  similar documents
V. I. Petrov, O. V. Shatalova, A. S. Gerasimenko, V. S. Gorbatenko
"... antagonists (warfarin) or with direct oral anticoagulants. A high risk of thromboembolic complications (CHA2DS ..."
 
Vol 15, No 4 (2019) Optimization of Pharmacotherapy with Direct Oral Anticoagulants: the Need to Choose the Right Dosage Regimen Abstract  similar documents
A. I. Kochetkov, O. D. Ostroumova
"... of evidence showing their high safety and efficacy, which in some cases exceed those of warfarin, and also ..."
 
Vol 15, No 6 (2019) Adherence to Treatment with New Oral Anticoagulants in Atrial Fibrillation Patients in Real Clinical Practice (Results of the ANTEY Study) Abstract  similar documents
S. Yu. Martsevich, Yu. V. Lukina, N. P. Kutishenko, S. N. Tolpygina, V. P. Voronina, N. A. Dmitrieva, O. V. Lerman, N. A. Komkova
"... recommended the use of rivaroxaban; 47 (23.4%) – the use of dabigatran and 43 (21.4%) – the use of apixaban ..."
 
Vol 9, No 1 (2013) OUTPATIENT REGISTER OF CARDIOVASCULAR DISEASES IN THE RYAZAN REGION (RECVASA): PRINCIPAL TASKS, EXPERIENCE OF DEVELOPMENT AND FIRST RESULTS Abstract  PDF (Eng)  similar documents
S. A. Boytsov, S. S. Yakushin, S. Yu. Martsevich, M. M. Lukyanov, N. N. Nikulina, A. V. Zagrebelny, A. N. Vorobyov, K. G. Pereverseva, E. A. Pravkina, A. D. Deev, E. Yu. Andreenko, A. I. Ershova, A. N. Meshkov, R. P. Myasnikov, S. E. Serdyuk, М. S. Kharlap
"... , coronary angiography use, as well as a scarce prescription of warfarin in AF and statins ..."
 
1 - 100 of 102 Items 1 2 > >> 

Search tips:

  • Search terms are case-insensitive
  • Common words are ignored
  • By default articles containing any term in the query are returned (i.e., OR is implied)
  • Make sure that a word exists in an article by prefixing it with +; e.g., +journal +access scholarly academic
  • Combine multiple words with AND to find articles containing all terms; e.g., education AND research
  • Exclude a word by prefixing it with - or NOT; e.g., online -politics or online NOT politics
  • Search for an exact phrase by putting it in quotes; e.g., "open access publishing". Hint: Quoting Chinese or Japanese words will help you to find exact word matches in mixed-language fields, e.g. "中国".
  • Use parentheses to create more complex queries; e.g., archive ((journal AND conference) NOT theses)